TANGENT study design: a phase III, randomized study of emactuzumab for the treatment of tenosynovial giant cell tumors. [PDF]
Gelderblom H +9 more
europepmc +1 more source
Pexidartinib: Current advances in the symptomatic treatment of tenosynovial giant cell tumors. [PDF]
Yuan Y, Zhang Z, Jiang Y, Ye T, Chen J.
europepmc +1 more source
Open synovectomy for treatment of tenosynovial giant cell tumors of the knee in children. [PDF]
Georgiev H +5 more
europepmc +1 more source
Tenosynovial Giant Cell Tumors: A Musculoskeletal Case Series. [PDF]
Yip FC +4 more
europepmc +1 more source
Vimseltinib: A novel colony stimulating factor 1 receptor (CSF1R) inhibitor approved for treatment of tenosynovial giant cell tumors (TGCTs). [PDF]
Dou F, Lu D, Gao J.
europepmc +1 more source
Long term term follow-up of tyrosine kinase inhibitors treatments in inoperable or relapsing diffuse type tenosynovial giant cell tumors (dTGCT). [PDF]
Brahmi M +16 more
europepmc +1 more source
Real-world drug utilization and treatment patterns in patients with tenosynovial giant cell tumors in the USA. [PDF]
Dharmani C +8 more
europepmc +1 more source
Multiportal Arthroscopy-assisted Surgical Resection of Diffuse-type Tenosynovial Giant Cell Tumors in the Ankle Joint Yields Favorable Clinical Outcomes: A Retrospective Study. [PDF]
Zhang J +9 more
europepmc +1 more source
Molecular Profiling of Atypical Tenosynovial Giant Cell Tumors Reveals Novel Non-CSF1 Fusions. [PDF]
Vougiouklakis T +4 more
europepmc +1 more source
Tenosynovial Giant Cell Tumors in Children: A Similar Entity Compared With Adults. [PDF]
Mastboom MJL +6 more
europepmc +1 more source

